| Literature DB >> 34822484 |
Lu-Ting Dai1, Li Yang2, Fan-Dong Kong3, Qing-Yun Ma2, Qing-Yi Xie2, Hao-Fu Dai4, Zhi-Fang Yu1, You-Xing Zhao2.
Abstract
Four new indole-diterpenoids, named penerpenes K-N (1-4), along with twelve known ones (5-16), were isolated from the fermentation broth produced by adding L-tryptophan to the culture medium of the marine-derived fungus Penicillium sp. KFD28. The structures of the new compounds were elucidated extensively by 1D and 2D NMR, HRESIMS data spectroscopic analyses and ECD calculations. Compound 4 represents the second example of paxilline-type indole diterpene bearing a 1,3-dioxepane ring. Three compounds (4, 9, and 15) were cytotoxic to cancer cell lines, of which compound 9 was the most active and showed cytotoxic activity against the human liver cancer cell line BeL-7402 with an IC50 value of 5.3 μM. Moreover, six compounds (5, 7, 10, 12, 14, and 15) showed antibacterial activities against Staphylococcus aureus ATCC 6538 and Bacillus subtilis ATCC 6633.Entities:
Keywords: Penicillium sp.; antibacterial activity; cytotoxicity; indole-diterpenoids; marine-derived fungus
Mesh:
Substances:
Year: 2021 PMID: 34822484 PMCID: PMC8619218 DOI: 10.3390/md19110613
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1The chemical structures of compounds 1–16.
Figure 2Key COSY and HMBC correlations of compounds 1–4.
Figure 3Key ROESY correlations of compounds 1–4.
Figure 4Experimental and calculated ECD curves for compound 1 (A); compound 2 (B); compound 3 (C).
1H NMR (500 and 600 MHz) data of 1–4 in DMSO-d6.
| Position | 1 | 2 | 3 | 4 |
|---|---|---|---|---|
| 2 | 7.04 (1H, s) | |||
| 4 | 7.55 (1H, d, 8.0) | |||
| 5 | 1.92 (1H, m) | 1.88 (1H, overlap) | 6.93 (1H, t, 8.0) | 2.01 (1H, m) |
| 1.80 (1H, m) | 1.60 (1H, overlap) | 1.94 (1H, m) | ||
| 6 | 1.51 (1H, m) | 1.90 (1H, m) | 7.02 (1H, t, 8.0) | 1.72 (1H, overlap) |
| 1.62 (1H, overlap) | 1.48 (1H, m) | 2.20 (1H, m) | ||
| 7 | 3.03 (1H, dd, 12.1, 3.8) | 3.49 (1H, dd, 9.7, 7.0) | 7.30 (1H, d, 8.0) | 4.46 (1H, m) |
| 8 | 2.07 (1H, m) | |||
| 3.15 (1H, d, 13.3) | ||||
| 9 | 3.10 (1H, dd, 12.0, 2.7) | 1.81 (1H, m) | 5.05 (1H, s) | |
| 10 | 1.41 (1H, m) | 4.04 (1H, dd, 2.1, 6.7) | 1.10 (1H, m) | |
| 1.62 (1H, overlap) | 1.65 (1H, m) | |||
| 11 | 1.74 (1H, m) | 1.88 (1H, overlap) | 1.26 (2H, m) | |
| 1.69 (1H, s) | 1.70 (1H, m) | |||
| 12 | 1.81 (1H, m) | 5.54 (1H, s) | ||
| 13 | 1.39 (1H, m) | 2.06 (1H, dd, 12.7, 3.1) | ||
| 14 | 0.83 (1H, m) | 1.74 (1H, m) | 2.55 (1H, m) | |
| 2.35 (1H, m) | 1.64 (1H, m) | |||
| 15 | 1.44 (1H, m) | 1.78 (1H, m) | 1.42 (2H, overlap) | 1.53 (1H, m) |
| 1.62 (1H, m) | 1.60 (1H, overlap) | 1.62 (1H, overlap) | ||
| 16 | 2.61 (1H, m) | 2.86 (1H, m) | 1.24 (1H, overlap) | 1.72 (1H, overlap) |
| 1.54 (1H, m) | 1.62 (1H, overlap) | |||
| 17 | 2.54 (1H, m) | 2.61 (1H, m) | 3.27 (1H, m) | 2.68 (1H, m) |
| 2.21 (1H, dd, 12.3, 10.9) | 2.29 (1H, dd, 11.2, 12.6) | |||
| 18 | 2.33 (1H, m) | |||
| 2.61 (1H, m) | ||||
| 19 | 1.02 (1H, m) | |||
| 1.47 (1H, m) | ||||
| 20 | 7.27 (1H, d, 7.5) | 7.27 (1H, d, 7.5) | 1.84 (2H, m) | |
| 21 | 6.91 (1H, t, 7.5) | 6.90 (1H, m) | 5.05 (1H, t, 7.6) | 7.27 (1H, m) |
| 22 | 6.91 (1H, t, 7.5) | 6.94 (1H, m) | 6.92 (1H, t, 7.9) | |
| 23 | 7.24 (1H, d, 7.5) | 7.26 (1H, d, 7.5) | 1.55 (3H, s) | 6.96 (1H, t, 7.9) |
| 24 | 1.62 (3H, s) | 7.27 (1H, m) | ||
| 25 | 0.94 (3H, s) | 0.94 (3H, s) | 0.94 (3H, s) | |
| 26 | 1.13 (3H, s) | 1.17 (3H, s) | 1.11 (3H, s) | 1.01 (3H, s) |
| 27 | 0.62 (3H, s) | 0.82 (3H, s) | ||
| 28 | 1.08 (3H, s) | 1.26 (3H, s) | ||
| 29 | 1.03 (3H, s) | 1.24 (3H, s) | 1.14 (3H, s) | |
| 30 | 3.69 (1H, m) | 1.13 (3H, s) | ||
| 3.86 (1H, m) | ||||
| 1-NH | 10.55 (1H, s) | 10.68 (1H, s) | 10.67 (1H, s) | 10.72(1H, s) |
| 14-OH | 4.04 (1H, s) | |||
| 17-OH | 4.22 (1H, d, 4.8) | |||
| 10-OH | 4.88 (1H, s) | |||
| 27-OH | 4.16 (1H, s) | |||
| 28-OH | 4.77 (1H, s) | |||
| 30-OH | 4.07 (1H, s) |
Compound 1 was measured with 500 MHz 1H NMR. Compounds 2, 3, and 4 were measured with 600 MHz 1H NMR.
13C NMR (125 and 150 MHz) data of 1–4 in DMSO-d6.
| Position | 1 | 2 | 3 | 4 |
|---|---|---|---|---|
|
|
|
|
| |
| 2 | 151.5, C | 150.9, C | 122.6, CH | 150.2, C |
| 3 | 52.9, C | 50.8, C | 114.4, C | 42.5, C |
| 3a | 127.6, C | |||
| 4 | 39.9, C | 38.5, C | 118.7, CH | 50.0, C |
| 5 | 32.7, CH2 | 30.6, CH2 | 117.9, CH | 30.8, CH2 |
| 6 | 24.5, CH2 | 23.2, CH2 | 120.6, CH | 30.0, CH2 |
| 7 | 85.2, CH | 78.2, CH | 111.2, CH | 83.0, CH |
| 7a | 136.3, C | |||
| 8 | 25.5, CH2 | |||
| 9 | 84.9, CH | 109.8, C | 42.9, CH | 102.3, CH |
| 10 | 25.7, CH2 | 73.1, CH | 27.2, CH2 | |
| 11 | 23.8, CH2 | 43.7, CH2 | 20.7, CH2 | 166.8, C |
| 12 | 48.8, C | 84.6, C | 41.1, CH | 113.1, CH |
| 13 | 46.9, CH | 38.8, CH | 42.0, C | 163.1, C |
| 14 | 31.8, CH2 | 26.2, CH2 | 76.4, C | 42.8, CH |
| 15 | 21.3, CH2 | 25.2, CH2 | 29.9, CH2 | 25.6, CH2 |
| 16 | 49.0, CH | 49.0, CH | 28.5, CH2 | 23.9, CH2 |
| 17 | 27.3, CH2 | 27.1, CH2 | 71.5, CH | 48.7, CH |
| 18 | 116.1, C | 115.9, C | 40.6, C | 26.9, CH2 |
| 19 | 124.6, C | 124.4, C | 37.0, CH2 | 115.8, C |
| 20 | 117.8 CH | 117.7, CH | 21.2, CH2 | 124.3, C |
| 21 | 118.6, CH | 118.5, CH | 125.3, CH | 117.7, CH |
| 22 | 119.3, CH | 119.4, CH | 129.8, C | 118.5, CH |
| 23 | 112.0, CH | 111.9, CH | 17.5, CH3 | 119.5, CH |
| 24 | 140.4, C | 140.1, C | 25.6, CH3 | 111.9, CH |
| 25 | 14.8, CH3 | 14.4, CH3 | 14.6, CH3 | 140.1, C |
| 26 | 19.5, CH3 | 16.7, CH3 | 16.3, CH3 | 14.7, CH3 |
| 27 | 70.7, C | 70.9, C | 17.2, CH3 | 15.4, CH3 |
| 28 | 26.9, CH3 | 26.4, CH3 | 69.9, C | |
| 29 | 24.9, CH3 | 24.7, CH3 | 24.0, CH3 | |
| 30 | 58.5, CH2 | 23.8, CH3 |
Compound 1 was measured with 125 MHz 13C NMR. Compounds 2, 3, and 4 were measured with 150 MHz 13C NMR.
Cytotoxicity of compounds 4, 9, and 15.
| Compound | IC50 (μM) | ||
|---|---|---|---|
| HeLa | A549 | BeL-7402 | |
|
| 36.3 | >50 | >50 |
|
| >50 | 28.4 | 5.3 |
|
| 33.1 | 24.4 | 40.6 |
| Cisplatin a | 8.6 | 4.5 | 4.1 |
a Positive control.
Antibacterial activities of compounds 5, 7, 10, 12, 14, and 15.
| Compound | MIC(μg/mL) | |
|---|---|---|
|
|
| |
|
| 128 | 32 |
|
| 64 | 16 |
|
| 64 | 64 |
|
| 64 | 128 |
|
| 64 | >128 |
|
| 32 | >128 |
| Ampicillin a | <1 | <1 |
a Positive control.